Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($2.09), $0.19 better than the analyst estimate of ($2.28). Revenue for the quarter came in at $21.03 million versus the consensus estimate of $15.12 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.